GRAIL is trading 4.01% down now at $72.45, reversing after three consecutive advancing sessions; no reliable source identifies a new company-specific announcement on August 12, 2026, directly explaining the decline.
- Recent coverage focuses on GRAIL’s August 5 earnings: $44.7 million revenue but continuing losses.
- An FDA advisory committee review is scheduled for September 23.
- These developments provide background, not a confirmed catalyst for today’s move.